Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Localized heat application as a strategy for enhanced oral peptide absorption - A proof-of-concept study.

International journal of pharmaceutics·2026
Same author

VRK1 co-delivery mitigates DNA clustering by BAF in TFAMoplex transfection.

Materials today. Bio·2025
Same author

Overcoming the gastrointestinal mucus barrier: Zinc-dependent modulation of mucinase activity.

International journal of pharmaceutics·2025
Same author

Corrigendum to 'A biodegradable suction patch for sustainable transbuccal peptide delivery' [J Control Release. 384 (2025) 113947].

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

Isolation of bacterial extracellular vesicles from raw samples using a portable microstructured electrochemical device.

Drug delivery and translational research·2025
Same author

Targeted oral delivery of microencapsulated TNF-α siRNA in an experimental model of colitis.

Drug delivery and translational research·2025

Related Experiment Video

Updated: Jul 9, 2026

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Brain targeting using novel lipid nanovectors.

Arnaud Béduneau1, François Hindré, Anne Clavreul

  • 1Inserm, U646, Angers, F-49100 France, Université d'Angers, Angers, F-49100 France.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|December 7, 2007
PubMed
Summary

Novel nanovectors, lipid nanocapsules (LNC) conjugated with antibodies, show promise for delivering drugs to the brain. These targeted nanovectors significantly increased brain concentrations compared to non-targeted ones.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jul 9, 2026

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications

Published on: November 17, 2015

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Area of Science:

  • Nanomedicine
  • Neuroscience
  • Biotechnology

Background:

  • Developing effective brain drug delivery systems is challenging due to the blood-brain barrier.
  • Lipid nanocapsules (LNC) are promising nanocarriers for drug delivery.
  • Targeting specific receptors on the cerebral endothelium can enhance brain penetration.

Purpose of the Study:

  • To evaluate novel antibody-conjugated lipid nanocapsules (LNC) for targeted delivery of lipophilic radionuclides and therapeutics to the brain.
  • To assess the efficacy of OX26 monoclonal antibody (OX26 MAb) and Fab' fragments in targeting the transferrin receptor (TfR) on brain endothelial cells.
  • To determine the biodistribution and brain accumulation of targeted LNC in vivo.

Main Methods:

  • Conjugation of LNC with OX26 MAb and Fab' fragments targeting the transferrin receptor (TfR).
  • In vitro demonstration of specific association of immunonanocapsules with rat brain capillary endothelial cells.
  • In vivo biodistribution studies in healthy rats using (188)Re-labeled lipophilic immunonanocapsules.

Main Results:

  • Immunonanocapsules showed specific binding to brain capillary endothelial cells.
  • Brain concentrations of Fab'-immunonanocapsules and OX26-immunonanocapsules were 1.5- and 2-fold higher, respectively, than non-targeted LNC at 24 hours.
  • Fab' fragments prolonged nanovector vascular residence time, but whole antibodies exhibited higher TfR affinity.

Conclusions:

  • Antibody-conjugated LNC effectively target the brain's transferrin receptor, enhancing brain accumulation of nanovectors.
  • This targeted nanodelivery approach holds significant potential for treating brain diseases.
  • Further research into optimizing nanovector design, like fragment selection, is warranted for improved therapeutic outcomes.